ASCO 2026: Sustained MRD and Outcomes in Multiple Myeloma

At ASCO 2026, Mattia D'Agostino, MD, Assistant Professor, University of Turin, Italy, presented long-term follow-up data from the FORTE trial. In this MEDtalk, he shares findings showing that sustained MRD negativity during maintenance therapy was associated with improved long-term outcomes in transplant-eligible patients with newly diagnosed multiple myeloma and explores the potential role of prolonged MRD monitoring in defining treatment success.